Healthcare provider profile · identity verified

Ellen Jane Moore, MD

Internal Medicine · ASHEVILLE, NC · NPI 1912226960

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	313	80
Atorvastatin Calcium	Atorvastatin Calcium	282	102
Amlodipine Besylate	Amlodipine Besylate	272	81
Levothyroxine Sodium	Levothyroxine Sodium	250	76
Rosuvastatin Calcium	Rosuvastatin Calcium	226	67
Omeprazole	Omeprazole	199	74
Eliquis	Apixaban	189	42
Lisinopril	Lisinopril	179	63
Metoprolol Succinate	Metoprolol Succinate	176	48
Lorazepam	Lorazepam	149	36
Alprazolam	Alprazolam	148	37
Tramadol Hcl	Tramadol Hcl	144	26
Escitalopram Oxalate	Escitalopram Oxalate	131	43
Gabapentin	Gabapentin	122	35
Furosemide	Furosemide	106	31
Hydrochlorothiazide	Hydrochlorothiazide	102	39
Zolpidem Tartrate	Zolpidem Tartrate	102	30
Simvastatin	Simvastatin	100	36
Pantoprazole Sodium	Pantoprazole Sodium	98	32
Duloxetine Hcl	Duloxetine Hcl	91	25
Pravastatin Sodium	Pravastatin Sodium	84	32
Metformin Hcl Er	Metformin Hcl	80	28
Shingrix	Varicella-Zoster Ge/As01b/Pf	80	61
Synthroid	Levothyroxine Sodium	79	23
Clonazepam	Clonazepam	78	18
Potassium Chloride	Potassium Chloride	77	19
Jardiance	Empagliflozin	76	20
Spironolactone	Spironolactone	76	19
Tamsulosin Hcl	Tamsulosin Hcl	74	28
Bupropion Xl	Bupropion Hcl	66	19
Trazodone Hcl	Trazodone Hcl	64	20
Sertraline Hcl	Sertraline Hcl	57	21
Metformin Hcl	Metformin Hcl	54	20
Famotidine	Famotidine	50	14
Citalopram Hbr	Citalopram Hydrobromide	49	18
Fluoxetine Hcl	Fluoxetine Hcl	48	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	11
Prednisone	Prednisone	46	24
Metoprolol Tartrate	Metoprolol Tartrate	44	16
Carvedilol	Carvedilol	43	14
Fluticasone Propionate	Fluticasone Propionate	43	24
Albuterol Sulfate Hfa	Albuterol Sulfate	42	14
Allopurinol	Allopurinol	42	15
Atenolol	Atenolol	42	13
Ozempic	Semaglutide	41	suppressed
Ibandronate Sodium	Ibandronate Sodium	36	13
Meloxicam	Meloxicam	36	12
Propranolol Hcl	Propranolol Hcl	36	13
Olmesartan Medoxomil	Olmesartan Medoxomil	35	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	11
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Donepezil Hcl	Donepezil Hcl	32	suppressed
Xarelto	Rivaroxaban	32	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	suppressed
Estradiol	Estradiol	31	14
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Glimepiride	Glimepiride	30	suppressed
Irbesartan	Irbesartan	30	11
Warfarin Sodium	Warfarin Sodium	29	suppressed
Telmisartan	Telmisartan	27	suppressed
Benazepril Hcl	Benazepril Hcl	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Myrbetriq	Mirabegron	21	suppressed
Alendronate Sodium	Alendronate Sodium	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Trulicity	Dulaglutide	20	suppressed
Pregabalin	Pregabalin	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Buspirone Hcl	Buspirone Hcl	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	17
Ondansetron Hcl	Ondansetron Hcl	17	11
Valsartan	Valsartan	17	suppressed
Lovastatin	Lovastatin	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Ezetimibe	Ezetimibe	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	14
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	14	suppressed
Testosterone	Testosterone	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Diazepam	Diazepam	13	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	13	11
Finasteride	Finasteride	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Aimovig Autoinjector	Erenumab-Aooe	12	suppressed
Colchicine	Colchicine	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error